LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Pestalozzi, B"
  2. AU="Filley, Christopher M."

Search results

Result 1 - 10 of total 153

Search options

  1. Article: Kongressberichte. St. Gallen 2013

    Pestalozzi, B.

    Schweizer Krebs-Bulletin

    2013  Volume 33, Issue 2, Page(s) 180

    Language English ; French ; German
    Document type Article
    ZDB-ID 1340924-4
    Database Current Contents Medicine

    More links

    Kategorien

  2. Article: INTERDISZIPLINARITÄT gross geschrieben!

    Pestalozzi, Bernhard

    Schweizer Zeitschrift für Onkologie

    2017  Volume 15, Issue 4, Page(s) 1

    Language German
    Document type Article
    ZDB-ID 2140740-X
    ISSN 1660-4369
    Database Current Contents Medicine

    More links

    Kategorien

  3. Article: How to remembet the St. Gallen Consensus Conference 2011

    Pestalozzi, B.

    Schweizer Krebs-Bulletin

    2011  Volume 31, Issue 2, Page(s) 178–182

    Language English ; French ; German
    Document type Article
    ZDB-ID 1340924-4
    Database Current Contents Medicine

    More links

    Kategorien

  4. Article: Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

    Pestalozzi, B

    Annals of oncology : official journal of the European Society for Medical Oncology

    2007  Volume 18 Suppl 2, Page(s) ii5–8

    MeSH term(s) Breast Neoplasms/diagnosis ; Breast Neoplasms/therapy ; Chemotherapy, Adjuvant ; Female ; Humans ; Mastectomy ; Mastectomy, Segmental ; Neoplasm Staging ; Risk Assessment
    Language English
    Publishing date 2007-05-07
    Publishing country England
    Document type Journal Article ; Practice Guideline
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdm015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Französisch bitte!

    Pestalozzi, B.

    Schweizerisches Medizin-Forum

    2010  Volume 10, Issue 28/29, Page(s) 479

    Language German
    Document type Article
    ZDB-ID 2220114-2
    ISSN 1424-3784
    Database Current Contents Medicine

    More links

    Kategorien

  6. Article: Medizinische Onkologie. Immuntherapie - nun auch für Kopf-Hals-Tumoren

    Rordorf, T. / Pestalozzi, B.

    Swiss medical forum

    2017  Volume 17, Issue 51/52, Page(s) 1156

    Language German
    Document type Article
    ZDB-ID 2220114-2
    ISSN 1424-3784
    Database Current Contents Medicine

    More links

    Kategorien

  7. Article: Medizinische Onkologie. Das Molekulare Tumorboard

    Britschgi, C. / Rechsteiner, M. / Weber, A. / Pestalozzi, B.

    Swiss medical forum

    2018  Volume 18, Issue 51/52, Page(s) 1097

    Language German
    Document type Article
    ZDB-ID 2220114-2
    ISSN 1424-3784
    Database Current Contents Medicine

    More links

    Kategorien

  8. Article: Kongressberichte. St. Gallen in Vienna 2015 - Convention Report

    Pestalozzi, B. C.

    Schweizer Krebs-Bulletin

    2015  Volume 35, Issue 2, Page(s) 204–210

    Language English ; French ; German
    Document type Article
    ZDB-ID 1340924-4
    Database Current Contents Medicine

    More links

    Kategorien

  9. Article: Zur Kasse, bitte!

    Pestalozzi, B.

    Schweizerisches Medizin-Forum

    2006  Volume 6, Issue 22, Page(s) 517

    Language German
    Document type Article
    ZDB-ID 2220114-2
    ISSN 1424-3784
    Database Current Contents Medicine

    More links

    Kategorien

  10. Article ; Online: ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.

    Forster-Sack, Miriam / Zoche, Martin / Pestalozzi, Bernhard / Witzel, Isabell / Schwarz, Esther Irene / Herzig, Joel Julien / Fansa, Hisham / Tausch, Christoph / Ross, Jeff / Moch, Holger / Varga, Zsuzsanna

    The journal of pathology. Clinical research

    2024  Volume 10, Issue 2, Page(s) e12362

    Abstract: Most invasive lobular breast carcinomas (ILBCs) are luminal-type carcinomas with an HER2-negative phenotype (ERBB2 or HER2 un-amplified) and CDH1 mutations. Rare variants include ERBB2-amplified subtypes associated with an unfavorable prognosis and less ... ...

    Abstract Most invasive lobular breast carcinomas (ILBCs) are luminal-type carcinomas with an HER2-negative phenotype (ERBB2 or HER2 un-amplified) and CDH1 mutations. Rare variants include ERBB2-amplified subtypes associated with an unfavorable prognosis and less response to anti-HER2 targeted therapies. We analyzed the clinicopathological and molecular features of ERBB2-amplified ILBC and compared these characteristics with ERBB2-unamplified ILBC. A total of 253 patients with ILBC were analyzed. Paraffin-embedded formalin-fixed tumor samples from 250 of these patients were added to a tissue microarray. Protein expression of prognostic, stem cell and breast-specific markers was tested by immunohistochemistry (IHC). Hybrid capture-based comprehensive genomic profiling (CGP) was performed for 10 ILBCs that were either fluorescent in situ hybridization (FISH) or IHC positive for HER2 amplification/overexpression and 10 ILBCs that were either FISH or IHC negative. Results were compared with a CGP database of 44,293 invasive breast carcinomas. The CGP definition of ERBB2 amplification was five copies or greater. A total of 17 of 255 ILBC (5%) were ERBB2 amplified. ERBB2-amplified ILBC had higher tumor stage (p < 0.0001), more frequent positive nodal status (p = 0.00022), more distant metastases (p = 0.012), and higher histological grade (p < 0.0001), and were more often hormone receptor negative (p < 0.001) and more often SOX10 positive (p = 0.005). ERBB2 short variant sequence mutations were more often detected in ERBB2-unamplified tumors (6/10, p = 0.027), whereas CDH1 mutations/copy loss were frequently present in both subgroups (9/10 and 7/10, respectively). Amplification of pathogenic genes were more common in HER2-positive ILBC (p = 0.0009). CDK12 gene amplification (≥6 copies) was detected in 7 of 10 ERBB2-amplified ILBC (p = 0.018). There were no CDK12 gene amplifications reported in 44,293 invasive breast carcinomas in the FMI Insights CGP database. ERBB2-amplified ILBC is a distinct molecular subgroup with frequent coamplification of CDK12, whereas ERBB2 sequence mutations occur only in ERBB2-unamplified ILBC. CDK12/ERBB2 co-amplification may explain the poor prognosis and therapy resistance of ERBB2-amplified ILBC.
    MeSH term(s) Female ; Humans ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Carcinoma, Lobular/genetics ; Carcinoma, Lobular/pathology ; Cyclin-Dependent Kinases/genetics ; In Situ Hybridization, Fluorescence ; Mutation ; Prognosis ; Receptor, ErbB-2/genetics
    Chemical Substances CDK12 protein, human (EC 2.7.11.22) ; Cyclin-Dependent Kinases (EC 2.7.11.22) ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2024-02-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 2814357-7
    ISSN 2056-4538 ; 2056-4538
    ISSN (online) 2056-4538
    ISSN 2056-4538
    DOI 10.1002/2056-4538.12362
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top